Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29992809 | 1.00 | CYP11B1 (0.45) | CYP11B1CYP11B2TRIM24TRIM33ALDH1A1 | |
| SCHEMBL3668845 | 0.78 | ALDH1A1 (0.39) | CYP11B1ALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL31288450 | 0.77 | — | — | |
| SCHEMBL9383289 | 0.77 | — | — | |
| SCHEMBL3596542 | 0.76 | ALDH1A1 (0.38) | CYP11B1ALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL20244713 | 0.76 | CYP11B2 (0.41) | CYP11B1CYP11B2ALDH1A1HPGDMAPT | |
| SCHEMBL31565019 | 0.76 | BACE1 (0.42) | CYP11B1ALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL30748563 | 0.76 | CYP11B1 (0.53) | CYP11B1ALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL580243 | 0.76 | KDM1A (0.39) | CYP11B1CYP11B2ALDH1A1HPGDMAPT | |
| SCHEMBL1543531 | 0.76 | CYP11B1 (0.53) | CYP11B1ALDH1A1HPGDMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361241-A1 | HPK1 INHIBITOR AND MEDICAL USE THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2025-11-27 | — | — | US | disclosed |
| US-20250223285-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4538274-A1 | HPK1 INHIBITOR AND MEDICAL USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2025-04-16 | — | — | EP | disclosed |
| EP-3601239-B1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2024-07-31 | — | — | EP | disclosed |
| CN-118344387-A | HPK1 inhibitor and application thereof in medicine | 贝达药业股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-2023237085-A1 | HPK1 INHIBITOR AND MEDICAL USE THEREOF | 贝达药业股份有限公司 | 2023-12-14 | — | — | WO | disclosed |
| CN-116003321-A | Novel heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-115969853-A | Novel heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115721648-A | Novel heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2023-03-03 | — | — | CN | disclosed |
| CN-112174935-B | Heterocyclic derivatives useful as SHP2 inhibitors | 北京加科思新药研发有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-8232289-B2 | Spiropiperidine compounds as ORL-1 receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-07-31 | — | — | US | disclosed |
| CN-102612520-A | Spiropiperidine compounds as orl-1 receptor antagonists | LILLY CO ELI | 2012-07-25 | — | — | CN | disclosed |
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| EP-2413941-A1 | RENIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2011060035-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060035-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361241-A1 | HPK1 INHIBITOR AND MEDICAL USE THEREOF | STK11, STK35, STK10 | CYP11B1 622/4885CYP11B2 723/4885TRIM24 2338/4885 |
| US-20250223285-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | CYP11B1 1462/4885CYP11B2 1789/4885TRIM24 2244/4885 |
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | CYP11B1 503/4885CYP11B2 396/4885TRIM24 3456/4885 |
| US-20110118251-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | OXER1, OGFRL1, ORMDL3 | CYP11B1 444/4885CYP11B2 325/4885TRIM24 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.